Pictet North America Advisors SA raised its holdings in AstraZeneca (NYSE:AZN) by 5.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 278,434 shares of the company’s stock after buying an additional 13,705 shares during the period. AstraZeneca accounts for about 2.9% of Pictet North America Advisors SA’s portfolio, making the stock its 9th largest holding. Pictet North America Advisors SA’s holdings in AstraZeneca were worth $19,121,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in AZN. Pinnacle Wealth Planning Services Inc. acquired a new position in AstraZeneca during the 4th quarter worth approximately $101,000. Delpha Capital Management LLC bought a new stake in shares of AstraZeneca in the 4th quarter valued at $152,000. Calton & Associates Inc. bought a new position in AstraZeneca during the fourth quarter worth $181,000. Whittier Trust Co. lifted its stake in shares of AstraZeneca by 420.0% in the first quarter. Whittier Trust Co. now owns 5,200 shares of the company’s stock valued at $182,000 after buying an additional 4,200 shares in the last quarter. Finally, Green Square Capital LLC bought a new position in shares of AstraZeneca in the fourth quarter valued at $200,000. Institutional investors own 15.59% of the company’s stock.
AstraZeneca traded up $0.40, hitting $36.73, during midday trading on Monday, MarketBeat Ratings reports. The company’s stock had a trading volume of 866,949 shares, compared to its average volume of 4,083,696. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. The company has a market capitalization of $92.02 billion, a price-to-earnings ratio of 8.58, a PEG ratio of 1.94 and a beta of 0.61. AstraZeneca has a 12 month low of $28.43 and a 12 month high of $36.75.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Friday, May 18th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.20. AstraZeneca had a return on equity of 30.12% and a net margin of 12.61%. The company had revenue of $5.18 billion during the quarter, compared to the consensus estimate of $5.24 billion. During the same period last year, the company earned $0.99 earnings per share. AstraZeneca’s revenue was down 4.2% on a year-over-year basis. sell-side analysts anticipate that AstraZeneca will post 1.7 EPS for the current fiscal year.
Several analysts have recently commented on the stock. ValuEngine downgraded shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 2nd. Zacks Investment Research lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Monday, April 9th. BMO Capital Markets set a $40.00 target price on shares of AstraZeneca and gave the company a “buy” rating in a research report on Thursday, March 22nd. Jefferies Group raised shares of AstraZeneca from a “hold” rating to a “buy” rating and lifted their target price for the stock from $28.43 to $36.70 in a research note on Monday, March 19th. Finally, Leerink Swann lifted their target price on shares of AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $38.12.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.